Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
株式のランク #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
株価
$0.01292666
最終同期: 2025-04-08
時価総額
$157.54K
変化(1日)
6.84%
変化(1年)
0.00%
GB
取引 Synairgen plc (SNG)

カテゴリー

Synairgen plc(SNG)の株価履歴
終値の最高値: $0.01 (2025-04-01)

終値の最安値: $2.04 (2004-10-01)
Synairgen plc の株価履歴(2004 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2025 -66.26%
2024 -44.21%
2023 -52.93%
2022 -92.61%
2021 77.16%
2020 1,567.16%
2019 -48.13%
2018 14.84%
2017 -14.89%
2016 -49.84%
2015 -35.02%
2014 -37.63%
2013 15.10%
2012 50.92%
2011 14.84%
2010 -28.85%
2009 88.33%
2008 -77.12%
2007 -24.86%
2006 -99.32%
2005 209.00%
2004 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE